JP2024520868A5 - - Google Patents
Info
- Publication number
- JP2024520868A5 JP2024520868A5 JP2023577405A JP2023577405A JP2024520868A5 JP 2024520868 A5 JP2024520868 A5 JP 2024520868A5 JP 2023577405 A JP2023577405 A JP 2023577405A JP 2023577405 A JP2023577405 A JP 2023577405A JP 2024520868 A5 JP2024520868 A5 JP 2024520868A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024093451A JP2024116283A (ja) | 2021-06-15 | 2024-06-10 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/066141 | 2021-06-15 | ||
| PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
| PCT/EP2022/066299 WO2022263508A1 (en) | 2021-06-15 | 2022-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024093451A Division JP2024116283A (ja) | 2021-06-15 | 2024-06-10 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2024520868A JP2024520868A (ja) | 2024-05-24 |
| JPWO2022263508A5 JPWO2022263508A5 (https=) | 2024-06-18 |
| JP2024520868A5 true JP2024520868A5 (https=) | 2024-06-18 |
| JP7513854B2 JP7513854B2 (ja) | 2024-07-09 |
Family
ID=77519090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577405A Active JP7513854B2 (ja) | 2021-06-15 | 2022-06-15 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
| JP2024093451A Pending JP2024116283A (ja) | 2021-06-15 | 2024-06-10 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024093451A Pending JP2024116283A (ja) | 2021-06-15 | 2024-06-10 | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11739145B2 (https=) |
| EP (1) | EP4355428A1 (https=) |
| JP (2) | JP7513854B2 (https=) |
| KR (1) | KR20240032847A (https=) |
| CN (1) | CN117858906A (https=) |
| AR (1) | AR126154A1 (https=) |
| AU (1) | AU2022292895A1 (https=) |
| BR (1) | BR112023026566A2 (https=) |
| CA (1) | CA3222300A1 (https=) |
| CL (1) | CL2023003725A1 (https=) |
| CO (1) | CO2023017378A2 (https=) |
| IL (1) | IL308072A (https=) |
| MX (1) | MX2023014666A (https=) |
| TW (1) | TW202317624A (https=) |
| WO (2) | WO2022262959A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| KR20250120305A (ko) * | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2025120867A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) * | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| US20230192903A1 (en) * | 2020-05-29 | 2023-06-22 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody against cldn18.2 and cd3 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en not_active Ceased
-
2022
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko active Pending
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 MX MX2023014666A patent/MX2023014666A/es unknown
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en not_active Ceased
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-06-15 JP JP2023577405A patent/JP7513854B2/ja active Active
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US12378313B2/en active Active
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
-
2024
- 2024-06-10 JP JP2024093451A patent/JP2024116283A/ja active Pending
-
2025
- 2025-07-11 US US19/267,078 patent/US20260035458A1/en active Pending